Recombinant MAPT (Tilavonemab Biosimilar) antibody

Catalog No. ABIN7538070

The Humanized Chimeric anti-MAPT (Tilavonemab Biosimilar) antibody has been validated for ELISA and WB. It is suitable to detect MAPT (Tilavonemab Biosimilar) in samples from Human.

Quick Overview for Recombinant MAPT (Tilavonemab Biosimilar) antibody (ABIN7538070)

Target: MAPT (Tilavonemab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Chimeric

Conjugate: This MAPT (Tilavonemab Biosimilar) antibody is un-conjugated

Application: ELISA, Western Blotting (WB)

Grade: Research Grade

Product Details anti-MAPT (Tilavonemab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Tilavonemab Biosimilar - Anti-MAPT mAb - Research Grade

Characteristics: Antibody Type: IgG4-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Purity: > 85%

Isotype: IgG4

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS buffer PH7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for MAPT (Tilavonemab Biosimilar)

Target: MAPT (Tilavonemab Biosimilar)

Target Type: Biosimilar

Background: Tilavonemab is a humanised anti-tau antibody that binds amino acids 25-30 near the N-terminal end of the tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates and reduces brain atrophy. Tilavonemab can be used in the study of Alzheimer's disease.

CAS-No: 2096513-89-0